Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.1M | $25.4M | $29.2M | $31.8M | $31.1M | $28.9M | $30.3M | $31.3M | $32.0M | $31.6M |
| Revenue growth | — | 9.8% | 15.1% | 8.9% | -2.1% | -7.3% | 5.0% | 3.3% | 2.0% | -1.3% |
| Operating income | $434K | $5.01M | $5.19M | $5.06M | $7.66M | $4.02M | $4.02M | -$12.3M | $3.48M | $482K |
| Operating margin | 1.9% | 19.7% | 17.8% | 15.9% | 24.6% | 13.9% | 13.3% | -39.3% | 10.9% | 1.5% |
| Net income | -$1.32M | $2.32M | -$855K | $2.29M | $3.62M | $2.08M | $2.77M | -$9.52M | $402K | -$2.43M |
| Net margin | -5.7% | 9.1% | -2.9% | 7.2% | 11.6% | 7.2% | 9.1% | -30.4% | 1.3% | -7.7% |
| EPS (diluted) | -$0.16 | $0.30 | -$0.11 | $0.27 | $0.45 | $0.25 | $0.33 | -$1.14 | $0.05 | -$0.30 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.99M | $5.72M | $5.33M | $6.29M | $8.47M | $7.93M | $8.57M | $8.92M | $6.01M | $5.48M |
| Capital expenditures | $343K | $98.3K | $446K | $662K | $100.0K | $1.83M | $12.2M | $6.84M | $2.40M | $230K |
| Free cash flow | $4.64M | $5.62M | $4.89M | $5.63M | $8.37M | $6.09M | -$3.60M | $2.08M | $3.61M | $5.25M |
| Share buybacks | $10.8M | $447K | — | $992K | — | $249K | $1.82M | $799K | $1.42M | $170K |
| Dividends paid | — | — | — | — | — | $0.00 | $7.67M | $0.00 | $2.02M | $3.23M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.50M | $6.28M | $6.04M | $6.54M | $10.4M | $8.26M | $1.70M | $406K | $561K | $319K |
| Total assets | $19.5M | $23.9M | $42.4M | $42.9M | $46.2M | $60.7M | $64.9M | $61.2M | $64.7M | $61.7M |
| Total liabilities | $35.0M | $36.4M | $51.3M | $49.8M | $48.9M | $56.5M | $66.4M | $72.3M | $77.9M | $80.3M |
| Long-term debt | $9.82M | $7.30M | $12.9M | $8.96M | $5.94M | $1.90M | $8.73M | $8.60M | $8.48M | $8.35M |
| Shareholders' equity | -$15.4M | -$12.5M | -$8.91M | -$6.95M | -$2.67M | $4.18M | -$1.52M | -$11.0M | -$13.2M | -$18.6M |
| Retained earnings | -$26.8M | -$24.5M | -$25.3M | -$22.4M | -$18.8M | -$16.7M | -$21.6M | -$31.2M | -$32.8M | -$38.4M |
| Shares (wtd avg diluted) | 8.11M | 7.65M | 7.46M | 8.41M | 8.14M | 8.36M | 8.48M | 8.34M | 8.21M | 8.07M |
Every figure is extracted from CRYO CELL INTERNATIONAL INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.